Quantitative physician surveys, qualitative KOL programmes, and market access intelligence across Europe, Middle East, and Africa — for pharma teams that need precision.
Each engagement is designed to answer a specific strategic question — not generate generic reports.
Large-scale statistical insights from physicians across European and Middle Eastern healthcare systems. From prescribing data to HTA decision-maker analysis and African market sizing.
Explore methods →Deep-dive interviews with key opinion leaders, hospital specialists, and Gulf healthcare leaders. Clinical perspectives structured into actionable strategic frameworks across Europe, Middle East, and Africa.
See our approach →Evidence-based pricing, payer engagement, and reimbursement modelling for G-BA, HAS, AIFA, and SFDA submissions. Bridging clinical evidence and commercial success across European and MEA markets.
Learn about HTA support →Systematic identification and influence mapping across European, Middle Eastern, and African markets. From leading university hospital consultants to Gulf ministry advisors and African health authority stakeholders.
View methodology →Quantified outcomes from recent pharmaceutical research projects.
Mapped 240+ oncology KOLs across 8 European and Gulf markets. Identified 18 tier-1 influencers who shaped HTA committee decisions and formulary access.
Surveyed 180 neurologists across KSA and UAE to quantify prescribing behaviour and unmet needs for a new CNS therapy.
Built the cost-effectiveness evidence package and payer engagement strategy that secured regulatory approval and formulary listing across Saudi Arabia and UAE.
In a market where competitors claim to be "the fastest growing" without a single verifiable source, we let our work speak for itself.
Our latest research covering regulatory shifts, market sizing, and strategic opportunities across Saudi Arabia, UAE, Kuwait, Egypt, South Africa, Kenya, and Nigeria.
No spam. Unsubscribe anytime.
BioNixus transformed our market access strategy with insights that were both rigorous and actionable. Their depth across the Middle East and Africa was something we hadn't found elsewhere.
The speed and quality of competitive intelligence exceeded our expectations. A genuinely strategic partner — not just a data vendor.
Their KOL mapping and patient journey work directly influenced our launch success in three European markets. Deep therapeutic understanding.
A comprehensive guide to SFDA's evolving orphan drug framework and the commercial implications for companies targeting the KSA rare disease market.
Read article →Mapping critical vulnerabilities in cross-border pharma logistics across the Gulf region.
Read article →Navigating the regulatory landscape in Kenya, Ethiopia, Nigeria, and South Africa for pharmaceutical market entry.
Read article →Book a 15-minute discovery call. No pitch deck — just a focused conversation about your research needs.